DDW News


Liver Diseases and Transplantation

Panel examines evolving strategies for treating, eliminating HCV

The AASLD Clinical Symposium HCV Treatment: Gastroenterologists Role in Eradicating HCV featured a panel of experts who discussed strategies to maximize the number of individuals who are treated for chronic HCV. “Despite recommendations and, in some states, mandates, we are falling behind on HCV screening,” said Robert S. Brown Jr., MD, MPH, AGAF.


Is an HCV cure rate of 100 percent realistic?

Although antiviral therapy has led to a cure rate of more than 90 percent of hepatitis C virus (HCV) cases, David E. Bernstein, MD, FAASLD, thinks more can be done to increase the cure rate. In this DDW Daily News video exclusive, Dr. Bernstein discusses several obstacles preventing patients’ access to curative therapies. He also addresses the benefits of HCV therapy and whether it’s possible to eradicate HCV and achieve 100 percent cure rate.


AASLD plenaries highlight clinical applications of liver disease research

AASLD will feature the most innovative research in its two plenary sessions at DDW®, according to AASLD President Ronald J. Sokol, MD, FAASLD. The Basic Science Plenary Session will be held Sunday morning and the Clinical Science Plenary Session will be held Monday morning. Each will offer something for all AASLD members and DDW attendees.


Year in Review session will highlight recent advances in liver disease

The editors of AASLD’s flagships journals, HEPATOLOGY and Liver Transplantation, have organized a comprehensive update on important advances in chronic liver disease for this year’s Hepatology Update: The Year in Review. David Cohen, MD, PhD, FAASLD, editor in chief of HEPATOLOGY, and Paul Martin, MD, FAASLD, editor in chief of Liver Transplantation, will moderate.